Patents by Inventor Nady Golestaneh

Nady Golestaneh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION
    Publication number: 20230417767
    Abstract: The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) polymerase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-I?) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-I? or AKT3 and/or higher acetylation levels of PGC-I? in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.
    Type: Application
    Filed: April 22, 2023
    Publication date: December 28, 2023
    Inventor: Nady Golestaneh
  • Biomarkers and therapeutic targets for abnormal retinal pigment epithelium
    Patent number: 11008617
    Abstract: The present invention relates to markers and therapeutic targets of abnormal retinal pigment epithelium (RPE).
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 18, 2021
    Assignee: GEORGETOWN UNIVERSITY
    Inventor: Nady Golestaneh
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION
    Publication number: 20190049465
    Abstract: The present invention is related to diagnostic, treatment and compound screening methods related to dry age-related macular degeneration (dry AM D). In select embodiments, the methods comprise determining expression or activity levels of NAD-dependent deacetylase sirtuin-1 (SI RT-1), AM P-activated protein kinase (AM PK), poly(adenosine diphosphate ribose) poly-merase-2 (PARP2), peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-I?) and/or mRNA levels of RAC-gamma serine/threonine-protein kinase (AKT3). In general, higher levels of PARP2, lower levels of PGC-I? or AKT3 and/or higher acetylation levels of PGC-I? in the samples are indicative that the subject or cells from which the samples are obtained are susceptible or are suffering from dry AMD.
    Type: Application
    Filed: February 6, 2017
    Publication date: February 14, 2019
    Applicant: Georgetown University
    Inventor: Nady GOLESTANEH
  • Biomarkers and Therapeutic Targets for Abnormal Retinal Pigment Epithelium
    Publication number: 20170022562
    Abstract: The present invention relates to markers and therapeutic targets of abnormal retinal pigment epithelium (RPE).
    Type: Application
    Filed: January 23, 2015
    Publication date: January 26, 2017
    Inventor: Nady GOLESTANEH
  • Compositions and Methods Comprising Biodegradable Scaffolds and Retinal Pigment Epithelial Cells
    Publication number: 20140341965
    Abstract: The invention relates to compositions comprising a monolayer of functional retinal pigment epithelial (RPE) cells attached to a transplantable, biodegradable scaffold. The invention also relates to methods of using these compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 20, 2014
    Applicant: Georgetown University
    Inventor: Nady Golestaneh